The utilization of anti-VEGF agents (e.g., bevacizumab) with the propensity to induce tumor hypoxia alongside cytotoxic agents has been tested extensively in a wide range of tumors and is now the standard of care in other GI malignancies, such as metastatic colorectal adenocarcinoma [48]. The gene discussed is VEGFA; the disease is neoplasm.